C
광동제약
009290KOSPI의약품 제조업50.8 / 100
Reference Date: 2026-04-13
Financial Score18.0 / 40
News Sentiment14.8 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but Operating Profit is on a declining trend. Declined 6.2% over the past month, and news sentiment is positive.
Company InformationBased on 2025 Annual Report
Business Overview
Guangdong Pharmaceutical operates through three divisions—OTC, ETC, and F&B—selling products like Cheongshimwon, Jeju Samdaewon, and Gardasil, with 98.6% of sales coming from the domestic market. In 2025, the company achieved sales of 10.11 trillion KRW and aims to expand into natural product markets, digital innovation, and healthcare platforms to become a 'Human Healthcare Brand' enterprise.
Number of Employees
1,022people
Average Salary
78.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
16.24Industry Average 14.803.0Point
Higher than industry avg (caution)
PBR
0.59Industry Average 1.045.5Point
Lower than industry avg (good)
ROE
3.21Industry Average 4.422.5Point
Below industry avg
Debt Ratio
11.61Industry Average 11.984.0Point
In line with industry avg
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
1.0 / 3
Avg ▲4.7% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼12.7% (2-year basis)
ROE Trend
2.0 / 4
Avg ROE 5.7% (declining, 3yr)
Detailed News Sentiment
29 totalPositive 9Neutral 15Negative 0Average Sentiment Score 61.2
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position5.0Point
52w mid range (54%)
Current 8,460Won52-week high 11,08052-week low 5,290
1-month return2.0Point
1m -6.21% (slight drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
5 totalPositive 0Neutral 5Negative 0
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
- Neutral정기주주총회결과2026-03-26
- Neutral주요사항보고서(자기주식처분결정)2026-03-26
- Neutral사업보고서 (2025.12)2026-03-18
- Neutral감사보고서제출2026-03-18